Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS)

Table 3 Summary of adverse events during the dose adjustment and primary treatment period, and maintenance period

Incidence, n (%)	NNS/CANDLE (N = 5) n (%)	SAVI (N = 3) n (%)	AGS (N = 1) n (%)	Total (N = 9) n (%)
TEAE^a	5 (100.0)	3 (100.0)	1 (100.0)	9 (100.0)
Severe TEAEs^b	2 (40.0)	1 (33.3)	0 (0.0)	3 (33.3)
Moderate TEAEs^b	2 (40.0)	0 (0.0)	0 (0.0)	2 (22.2)
Mild TEAEs^b	1 (20.0)	2 (66.7)	1 (100.0)	4 (44.4)
Death^c	0 (0.0)	1 (33.3)^c	0 (0.0)	1 (11.1)
SAE	2 (40.0)	1 (33.3)^c	0 (0.0)	3 (33.3)
Discontinuation from study and study treatment due to AE	1 (20.0)	1 (33.3)^c	0 (0.0)	2 (22.2)

AE adverse event, AGS Aicardi-Goutières Syndrome, n number of patients with at least one adverse event per event type, NNS/CANDLE Nakajo-Nishimura syndrome/chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature, SAE serious adverse event, SAVI STING-associated vasculopathy with onset during infancy, STING stimulator of interferon genes, TEAE treatment-emergent adverse event
^aPatients may be counted in more than one category
^bPatients with multiple occurrences of the same event are counted under the highest severity
^cThe death event was included in SAE and discontinuations due to AE

ISSN: 1546-0096